Peng J. et al. and Kumar A. et al. reported that DOX-loaded HER2 antibody (Trastuzumab or Herceptin)-conjugated micelles had a potential or promising role on HER2-positive breast cancer cells, in terms of increasing the efficiency of targeted nanoparticles [20,59]. The gene discussed is ERBB2; the disease is breast carcinoma.